NEW YORK, May 6, 2024 /PRNewswire/ Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and.
EQS-News: Immunic AG: Immunic to Participate in Investor and Scientific Conferences in May finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Primary Progressive Multiple Sclerosis Treatment Market Size, openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.
A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).
In a pioneering effort to address the limited treatment options for Australians grappling with progressive multiple sclerosis (MS), a groundbreaking adaptive clinical trial named PLATYPUS (PLatform Adaptive Trial for remYelination and neuroProtection in mUltiple Sclerosis) is set to commence in January 2024. The initiative, boasting an initial funding of $4 million, marks the first-ever adaptive […]